๐ Patent-filing update ยท IPflair ยท all-8 held to single FD 03 Jul 2026 (was two-batch 22/26 Jun) ยท 19 Jun 2026
Patent filing is live via IPflair (selected 19 Jun) as a single batch โ all 8 (P01ยทP02ยทP02bยทP03ยทP04ยทP05ยทP09ยทP10) held to one FD 22 Jun / 26 Jun 2026 03 Jul 2026. ยง39 clock starts 03 Jul ยท complete specifications due 22 Jun / 26 Jun 2027 03 Jul 2027 (ยง9(1)) ยท PCT decision 26 Dec 2026 03 Jan 2027 ยท US/EU national-phase entry 26 Dec 2028 03 Jan 2029 ยท Request for Examination 26 Jan 2029 03 Feb 2029. Marketing public-disclosure window also shifts: founder 1-to-1 outbound to known DP targets continues pre-FD under NDA; public marketing (newsletter ยท pillar pages ยท founder LinkedIn cadence ยท PR note ยท webinar invites) unlocks Mon 29 Jun 2026 Tue 07 Jul 2026 (W5) post-FD. Engineering W1-W14 pilot timeline holds: demo lock Fri 26 Jun ยท Verified Go-Live Decision Tue 01 Sep.
Two-lane motion ยท Lane A US biotech/ATMP + Lane B India CDMO ยท design-partner-led ยท owner: Vimal ยท prepared 2026-06-12 ยท updated 2026-06-25 (AmpleLogic competitive set ยท India DP v1.2 founding-partner pricing ยท Apollo target lists ยท marketing claim review)
2
GTM lanes (A: US ยท B: India)
14
Lane B First Wave accounts
4
ACV ladder phases
12
GTM workstreams
3โ5
Design-partner target (2027)
๐ก Insights & Next Actions
2026-06-25 update: Founding Partner Cohort 1 pricing locked (Phase 0 โน3L ยท Phase 1 โน9L ยท first 2 by 31 Dec 2026; standard list = ACV ladder below). AmpleLogic competitive set built (brief ยท 17-slide deck ยท battlecard incl. TCO/sovereign-AI). India DP outreach v1.2 + Apollo target lists (119-company master DP list ยท 65 curated Lane-A ยท โ enriched QA contacts). Marketing newsletter + 4 emails claim-cleaned (FDA CSA date corrected to 24 Sep 2025). See GTM Document Library.
The funnel top is the 26 Jun demo: demo โ Phase-0 Evidence Mapping Sprint โ signed LOI โ these are the same qualified-evidence event Investment GATE 2 depends on.
Lane B is the wedge: 14 First Wave India CDMO accounts under Schedule M + USFDA pressure โ CDSCO + Schedule M control mapping is the opener. Lane A = buyable US emerging biotech / ATMP / cell-and-gene + small specialty CDMO accounts (Forge, Nuvation, Quotient, LGM, Aragen + 5 more), reached via the founder's clinical-quality network as warm intros ONLY โ former employers BMS, Genentech, Alumis, Arcellx are intro/reference, never targets.
Highest-leverage action: lock 3 design-partner anchors (DP-1..4 profiles). Ship the India-variant capabilities deck (CDSCO-led) and the founder thought-leadership content engine (Annex 22 / FDA WL 722591 commentary).
Discipline: founder-led sales only โ no AEs, no paid ads pre-validation. Win on principled AI refusal + sealed evidence (the moat), not demand-gen.